X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Virtue SAB (sirolimusEFR), a proprietary, investigational, extended release formulation of sirolimus, to the artery during balloon angioplasty without the need for balloon coating or a permanent implant.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Virtue SAB
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Virtue SAB (sirolimus), a potent anti-inflammatory and anti-proliferative compound, has been used successfully in coronary drug-eluting stents. It provides mechanical dilatation (inhibiting the proliferation of cells), with the intended purpose of reducing restenosis.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Virtue SAB
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Under the terms of their collaboration agreement, Orchestra BioMed and Terumo plan to execute a global clinical program Virtue SAB (sirolimus), in an effort to gain regulatory approval for commercial sale of Virtue SAB in multiple markets and indications.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Virtue SAB
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Terumo
Deal Size: Undisclosed Upfront Cash: $30.0 million
Deal Type: Collaboration July 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
